Review Fees

                                                                                                                                              SIU-SOM IRB REVIEW FEES

                                                                                                                                                   (Effective May, 1, 2021)

 

Initial Full Board Review

Initial Expedited Review

Modifications/ Amendments

Continuing Review

Study Closure

Exemption/Non-Human Subject Research Determination

Administrative Review

Annual Monitoring

Industry Sponsored Protocols

$3,000

$3,000

$500

$1,000

$500

NA

NA

NA

*^SIU Investigator Initiated Protocols/ Federally Funded/ State Supported/ Non-Profit

No Charge

No Charge

No Charge

No Charge

No Charge

No Charge

NA

NA

Non-SIU Investigator Initiated Protocols

$1,400

$500

$100

$250

$100

$200

NA

NA

sIRB – SIU is a Relying Institution– Industry
Sponsored

NA

NA

NA

NA

NA

NA

$1,500

$500

sIRB – SIU is a Relying Institution (Federally
Funded)

NA

NA

NA

NA

NA

NA

No Charge

No Charge

sIRB – SIU is IRB of Record (Industry
Sponsored)

$3,500 Per relying
site

$3,500 Per relying
site

$800 Per affected
relying site

$1,600
Per relying
site with
study
activity
since last
approval

$500 Per relying site

NA

NA

NA

sIRB – SIU is IRB of Record (Federally
Funded)**

$1,400 Per relying
site

$1,400 Per
relying
site

$300 Per affected
relying site

$600
Per relying
site with
study
activity
since last
approval

No Charge

NA

NA

NA

*This may include non-SIU investigators if other agreements are in place
^This also includes non-sponsored projects conducted by SIU-employed investigators under the oversite of an SIU Department Chair
**The IRB may charge fees for serving as the single IRB of Record (sIRB) for federally funded, multi-site studies for any grant proposals
submitted to the NIH after January 2018. The NIH policy states that the IRB of Record should bill for these additional site fees as direct costs.
These fees should be included in grant proposals for federally funded, multi-site trials.